Bacteroides (Porphyromonas) gingivalis and Bacteroides (Porphyromonas) intermedius are metabolically diverse species of gram-negative anaerobic bacilli implicated in the etiology of human periodontal diseases (14, 25, 33, 35) . These diseases are characterized by gingival inflammation and loss of connective tissue and bone from around the roots of the teeth (13). B. gingivalis and B. intermedius are able to specifically recognize and bind the plasma protein fibrinogen with high affinity; in addition, they are able to proteolytically cleave fibrinogen (22, 23) . The bacterial components responsible for these interactions have not been identified, and the role of these interactions in the pathogenesis of periodontitis is unknown. Fibrinogen binding and cleaving activities may be important virulence factors for these bacteria. These interactions may promote adherence of bacteria to periodontal tissues, prevent elimination of bacteria by immune mechanisms, or contribute to tissue destruction by interfering with fibrin formation or lysing blood clots.
Bacteroides (Porphyromonas) gingivalis and Bacteroides (Porphyromonas) intermedius are metabolically diverse species of gram-negative anaerobic bacilli implicated in the etiology of human periodontal diseases (14, 25, 33, 35) . These diseases are characterized by gingival inflammation and loss of connective tissue and bone from around the roots of the teeth (13) . B. gingivalis and B. intermedius are able to specifically recognize and bind the plasma protein fibrinogen with high affinity; in addition, they are able to proteolytically cleave fibrinogen (22, 23) . The bacterial components responsible for these interactions have not been identified, and the role of these interactions in the pathogenesis of periodontitis is unknown. Fibrinogen binding and cleaving activities may be important virulence factors for these bacteria. These interactions may promote adherence of bacteria to periodontal tissues, prevent elimination of bacteria by immune mechanisms, or contribute to tissue destruction by interfering with fibrin formation or lysing blood clots.
When we initially examined the interactions of these bacteria with fibrinogen (22, 23) , we found that the characteristics of binding of both Bacteroides species to fibrinogen were very similar: the binding is rapid, reversible, saturable, and of high affinity (Kd 10 to 30 nM); however, degradation of fibrinogen appeared to involve a serine protease in B. intermedius and a thiol-dependent protease in B. gingivalis. Determination of the site or sites on human fibrinogen recognized by B. gingivalis and B. intermedius is important for several reasons. Knowledge of the recognition site would contribute to our understanding of the mechanism of the interaction and might clarify the role of these bacterial approximately 112 amino acid residues long and connect the central domain to the terminal domains. The binding site for S. aureus is reported to be located in the 15 amino acid residues that make up the carboxy terminus of the -y chain (-yc) (30) . Although there are many regions of the molecule that are sensitive to plasmin, cleavage at the protease-sensitive sites indicated generates fragments D1 and E. Fragments D1 and E correspond approximately to the terminal and central domains, respectively, except that parts of the coiled coil between the protease-sensitive site and the proximal or distal disulfide ring are part of the degradation products (indicated by boxes).
antibodies to fibrinogen fragments to inhibit interaction of the cells with the native fibrinogen molecule. A pentadecapeptide, which retained the ability to block fibrinogen binding to S. aureus and platelets, was recovered from a staphylococcal protease digest of a 27-residue CNBr peptide that contained the carboxy terminus of the fibrinogen -y chain (30) . This pentadecapeptide, which represents the 15-residue carboxy terminus of the y chain ( Fig. 1) , has been synthesized and reported to contain a cell-binding site for both S. aureus and human platelets (7, 30) . More recent studies have appeared which suggest that long-range intramolecular interactions are needed to stabilize the conformation assumed by fibrinogen chains in the native fibrinogen molecule (4, 5, 26) . Data presented in one of these studies (5) suggest that binding sites that have a strong dependence on native conformation will likely be destroyed as the secondary and tertiary structure of the native molecule is disrupted in the generation of chains or fragments. In attempting to determine the site(s) on human fibrinogen recognized by strains of B. gingivalis and B. intermedius, we have followed the approach of examining 1251-fibrinogen (125I-Fbg) binding by bacteria in the presence of fibrinogen chains and plasmin-generated fibrinogen fragments described above. Our results indicate that B. gingivalis and B. intermedius recognize different sites on the fibrinogen molecule, and we have tentatively identified the regions of the fibrinogen molecule where these Bacteroides species interact.
MATERIALS AND METHODS
Materials. Fibronectin-free human fibrinogen (L grade; Kabi, Stockholm, Sweden) and rabbit anti-human fibrinogen (anti-Fbg) immunoglobulin G (IgG) were prepared as previously described (23) . Bovine serum albumin, plasmin, ovalbumin, human IgG, fetuin, and lysostaphin were purchased from Sigma Chemical Co. (St. Louis, Mo.). Na125I (specific activity, 15 mCi/,tg) was purchased from Amersham Corp. (Arlington Heights, Ill.), and Sepharose CL-4B was purchased from Pharmacia Fine Chemicals (Piscataway, N.J.). All other chemicals were of reagent grade and purchased from commercial sources.
Preparation of staphylococcal fibrinogen receptor. A fibrinogen receptor from S. aureus Newman was prepared by using an approach similar to the one described by Froman et al. (10) for purification of a fibronectin receptor from the same organism. Bacterial cell walls were solubilized by digestion with lysostaphin in the presence of protease inhibitors, including 1 mM phenylmethylsulfonyl fluoride and 10 mM N-ethylmaleimide, followed by heat treatment at 88°C for 20 min and centrifugation (1, 350 x g, 20 min). The supernatant fraction (designated lysate) was supplemented with 1 mM phenylmethylsulfonyl fluoride and 10 mM EDTA, and the pH was adjusted to 7.4. The lysate of staphylococcal cells was chromatographed on a column of human fibrinogen-Sepharose CL-4B (3 by 20 cm; approximately 3 mg of fibrinogen per ml of gel) equilibrated with Tris-buffered saline (0.14 M sodium chloride, 50 mM Tris hydrochloride [pH 7.5] (11) . Reduced, alkylated chains were separated by ion-exchange chromatography, using carboxymethyl-Sepharose (Pharmacia) as described by Doolittle et (32) , harvested by centrifugation, washed three times with PBS, and resuspended in PBS at a cell density of 1 x 1010 to 2 x 1010 cells per ml as previously described (22) . Bacterial suspensions were stored for several weeks at 4°C before use in binding studies to reduce proteolytic activity (22) .
Binding of bacteria to labeled proteins. Bacteria (1 x 10' to 3 x 109 cells) were incubated with 2.5 x 104 to 5.0 x 104 cpm of radiolabeled protein in albumin-coated tubes containing 0.1% (wt/vol) bovine serum albumin, plus other additives as required, in a total volume of 0.5 ml. Tubes containing the incubation mixtures were rotated on a hematology mixer at 22°C for 15 min unless otherwise stated. This incubation time was chosen because there was little change in the amount of 125I-Fbg bound to bacteria between 15 and 30 min of incubation when cells stored at 4°C for several weeks were used in binding assays and protease inhibitors were included. Subsequently, 400 ,ul of the incubation mixture was placed in an albumin-coated tube and rapidly diluted with 3 ml of ice-cold PBS containing 0.02% (wt/vol) bovine serum albumin. The samples were centrifuged at 1,300 x g for 15 min in a swinging-bucket rotor, the supernatants were aspirated, and the radioactivity associated with the pelleted bacteria was measured in a gamma counter (LKB-Wallac, Turku, Finland). Radioactivity recovered from incubation mixtures containing no bacteria was considered to be background and was subtracted from that obtained for incubations containing bacteria. All samples were analyzed in triplicate unless otherwise noted. Plastic tubes holding incubation mixtures were precoated with bovine serum albumin to minimize unspecific binding of bacteria and proteins to the walls of the tubes. Incubations of labeled proteins with B. gingivalis strains were performed in the presence of 20 mM (final concentration) N-ethylmaleimide, and incubations of labeled proteins with B. intermedius strains were performed in the presence of 2 mM (final concentration) phenylmethylsulfonyl fluoride. At these concentrations of protease inhibitors, proteolysis of the native molecule and of prepared chains and fragments was completely blocked during the incubation periods, as confirmed by SDS-PAGE and autoradiography.
Specificity of binding of '251-protein to bacteria. Bacteria were incubated with competing protein for 15 min before addition of 1251I-protein, after which incubation was continued for an additional 15 min. The amount of radioactive material that bound to bacteria in the presence of the competing protein was determined as described above. Preparation of anti-Fbg IgG absorbed with fibrinogen fragments D. Rabbit anti-Fbg IgG was prepared as previously described (23) . After dialysis to PBS, the antibody (540 pug/ml) was absorbed with Mono Q-purified fragments D (100 p.gIml, final concentration) overnight at 4°C. The resulting solution was centrifuged at 50,000 x g for 3 h to remove precipitated protein. The supernatant fraction was passed over a protein A-Sepharose column (Pharmacia), which was eluted with 0.5 M NaCl followed by 3.0 M MgCl2. The fractions eluting with salt were dialyzed to PBS and analyzed by SDS-PAGE on 7.5% acrylamide gels. The runthrough from the protein A-Sepharose column contained some fragments D, but the bulk of the fragments D eluted in the 0. These specificity and reversibility data should be interpreted with caution for several reasons. Only one concentration (100 ,ug/ml) of competing and displacing ligands was used in this study. Although this concentration represented a large molar excess relative to that of the radiolabeled ligand, it may have been insufficient in some cases, particularly if the affinity of the labeled ligand for the bacteria was much greater than that of a competing or displacing component. In addition, the displacement studies were blocked either by the unlabeled chain or by fibrinogen, and there is no simple explanation for these findings. The studies of specificity and reversibility of ligand binding described above strongly support a fibrinogen-binding site for B. intermedius on fragments D and a fibrinogenbinding site for B. gingivalis on the -y chain. The next experiments were performed to further explore species differences in fibrinogen-binding sites.
Effect of anti-Fbg IgG on binding of fibrinogen fragments to bacteria. Previous results from our laboratory have shown that rabbit anti-Fbg IgG inhibits in a concentration-dependent manner the binding of '25I-Fbg to B. gingivalis and B.
intermedius strains (22, 23) . The data presented in Fig. 7 show the effect of absorption with fragments D, which should remove antibodies to the terminal domains of fibrinogen, on (Fig. 7a) . It also removed most of the antibody that inhibited binding of 1251I-Fbg to these bacteria (Fig. 7b) . In contrast, absorption of anti-Fbg IgG with fragments D had little effect on the ability of the antibody to block binding of 125I-Fbg to the B. gingivalis strain (Fig. 7c) . These data suggest that the B. intermedius strain binds fibrinogen in the D domain and that the B. gingivalis strain binds fibrinogen at a site remote from the D domains.
Effect of S. aureus fibrinogen receptor on binding of 125j_ Fbg to bacteria. Other bacteria have been reported to bind 125I-Fbg (16, 20, 30 (15, 16, 30) . The first approach relies on the assumption that small fragments of large ligands, like fibrinogen, can be generated that retain the binding site for cells. Fibrinogen fragments have been generated both chemically (by reduction and alkylation, treatment with CNBr, or both) and enzymatically (by digestion with plasmin or other proteases) and then tested for the ability to inhibit the interaction between cells and the native fibrinogen molecule (16, 30) . This approach has been technically problematic for several groups, including ours, because many of these fibrinogen fragments, particularly the reduced, alkylated a chains and some of the CNBr peptides, show a strong tendency to aggregate and are very insoluble in aqueous solvents (15) . These properties make binding studies difficult to perform and may account for a portion of the unexpected results obtained in some of our experiments, such as increased binding of iodinated chains to bacteria after addition of unlabeled chains.
Previous studies suggest that some epitopes present in native fibrinogen are destroyed and new epitopes are created when fibrinogen is chemically or enzymatically cleaved (4, 9) . Similar changes may also occur among receptor-binding sites. Nagy et al. (26) Recognition of a binding site in a protein by a cellular receptor or other interacting molecule may rely largely on the primary structure of the ligand in some cases, whereas in other cases recognition may rely largely on the conformation of the polypeptide chain (5, 27) . In cases where conformation is more important than primary structure for recognition, attempts to identify receptor-binding sites by testing the activity of peptides generated by disassembly methods that destroy native ligand conformations (i.e., reduction and alkylation) have a low probability of success.
To overcome technical difficulties of working directly with fibrinogen chains and fragments in solution, Hawiger et al. (15) have used a second approach, in which antibodies raised against isolated fibrinogen fragments are tested as potential inhibitors of binding of native ligand to cells. This approach is based on the assumption that antibodies generated against small ligand fragments will react with the same fragments in their native conformation in the parent molecule and block binding of cells to the ligand at or near the cell-binding site. A potential problem with this immunological approach is the possibility that antibodies, as they bind to the ligand molecule, may induce long-range conformational changes that affect the structure of a distant receptor-binding site. Consequently, an antibody may inhibit cell binding of a ligand by interacting with the ligand molecule at a substantial distance from the actual cell-binding site. (5, 7) . The interaction of the bacteria with all of the fibrinogen chains is surprising and somewhat more difficult to interpret. In a preliminary characterization of the binding of different fibrinogen chains to strains of the two Bacteroides species, we found that all chains bound to all bacterial cells. Further analysis revealed a substantial variation among different strains in the specificity and reversibility of their interactions with isolated fibrinogen chains. The reasons for these strain differences are not clear; however, little is known about the amount of strain-to-strain variability in outer membrane proteins of these Bacteroides species, and it is possible that the presence of capsular material could alter binding of cells to host tissue components (25) . Considering the magnitude of the disruption of the conformation of the native molecule when ot, ,, and -y chains are generated, it is not surprising that the studies performed failed to detect which chain or chains within the D fragments contain a cell-binding site for B. intermedius strains. Although the results are somewhat more ambiguous than those for the fragments D-B. intermedius interaction, our data support the presence of a binding site for B. gingivalis on the fibrinogen -y chain.
Despite the complexity of our data, certain conclusions can be drawn. First, B. gingivalis and B. intermedius preferentially bind fibrinogen at different sites. In the case of B. gingivalis, -y-chain binding mimics most closely the binding of native fibrinogen to bacteria. Since B. gingivalis recognizes intact y chain but not fragment D1 or E, which contain between them almost the entire -y chain (D1 contains approximately the carboxy-terminal three-fourths of the -y chain, and E contains approximately the amino-terminal onefourth), we hypothesize that B. gingivalis binds fibrinogen at the plasmin-sensitive site of the coiled-coil region between the D and E domains. With respect to B. intermedius strains, binding of fragments D mimics binding of native fibrinogen to bacteria, and it appears that a fibrinogen-binding site for B. intermedius is contained in fragments D. These conclusions are summarized in Fig. 9 . That B. gingivalis and B. intermedius species recognize different sites on the fibrinogen molecule was further demonstrated by the different effects that fragments D-absorbed anti-Fbg IgG and the S. aureus fibrinogen receptor had on the binding of 251I-Fbg to different strains of the two species. The results of this study and of others (4, 5, 26) highlight the difficulties involved in trying to find specific sites on large complex protein ligands, particularly sites whose activity is highly conformationally dependent, in ligand fragments that may contain the appropriate primary sequences but whose tertiary or quaternary structures may be different from those they assume in the native molecule.
The finding that B. gingivalis and B. intermedius bind fibrinogen at spatially distant and distinct sites may have clinical significance. The difference in fibrinogen recognition by these organisms might be exploited to develop new antimicrobial agents with specificity at the species level. In addition to being therapeutically useful, these agents may elucidate the role of a suspected virulence factor or a particular bacterial species in the pathogenesis and etiology of human periodontal diseases.
